Ebymect: Uses, Dosage & Side Effects

What Is Ebymect and What Is It Used For?

Ebymect is a fixed-dose combination oral medication developed by AstraZeneca that brings together two well-established antidiabetic agents in a single film-coated tablet. The medication contains dapagliflozin, a selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), and metformin hydrochloride, the most widely prescribed first-line treatment for type 2 diabetes worldwide. By combining these two agents with distinct and complementary mechanisms of action, Ebymect offers a convenient and effective approach to glycemic management that addresses multiple pathophysiological defects underlying type 2 diabetes.

Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic beta-cell dysfunction, leading to elevated blood glucose levels (hyperglycemia). If left inadequately treated, chronic hyperglycemia damages blood vessels and nerves throughout the body, leading to serious complications including cardiovascular disease, kidney failure (diabetic nephropathy), vision loss (diabetic retinopathy), and nerve damage (diabetic neuropathy). According to the International Diabetes Federation (IDF), approximately 537 million adults worldwide were living with diabetes in 2021, with type 2 diabetes accounting for approximately 90–95% of all cases. The global prevalence is projected to reach 783 million by 2045, making effective and accessible treatments critically important.

The dapagliflozin component of Ebymect works through an insulin-independent mechanism by selectively and reversibly inhibiting SGLT2, a protein located in the proximal convoluted tubule of the kidney. Under normal physiological conditions, SGLT2 is responsible for reabsorbing approximately 90% of the glucose filtered by the kidneys back into the bloodstream. By blocking this transporter, dapagliflozin prevents the reabsorption of glucose, causing approximately 70 grams of glucose per day to be excreted in the urine (glycosuria). This mechanism has the dual benefit of lowering blood glucose levels while also resulting in a caloric loss of approximately 280 kilocalories per day, which contributes to the modest weight loss observed with SGLT2 inhibitor therapy. Additionally, the osmotic diuresis associated with urinary glucose excretion leads to a mild reduction in blood pressure, which is a further beneficial effect for many patients with type 2 diabetes who commonly have coexisting hypertension.

The metformin component of Ebymect has been the cornerstone of type 2 diabetes treatment for over six decades and remains the recommended first-line pharmacological therapy by all major international guidelines, including those of the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the World Health Organization (WHO). Metformin works primarily by reducing hepatic glucose production through inhibition of gluconeogenesis and glycogenolysis. It also decreases intestinal absorption of glucose and improves peripheral insulin sensitivity by enhancing glucose uptake and utilization in skeletal muscle and adipose tissue. Unlike sulfonylureas and insulin, metformin does not cause hypoglycemia when used alone, does not promote weight gain, and has a well-established long-term safety profile.

The rationale for combining dapagliflozin and metformin in a fixed-dose tablet is supported by robust clinical evidence. Both the ADA and EASD guidelines recommend SGLT2 inhibitors as a preferred add-on therapy to metformin, particularly in patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), owing to the proven cardiovascular and renal protective effects of this drug class. The DECLARE-TIMI 58 trial, which enrolled more than 17,000 patients with type 2 diabetes, demonstrated that dapagliflozin significantly reduced the composite endpoint of cardiovascular death and hospitalization for heart failure compared with placebo. The DAPA-HF trial subsequently showed that dapagliflozin reduced the risk of worsening heart failure and cardiovascular death in patients with heart failure with reduced ejection fraction, regardless of whether they had diabetes. These landmark trials have positioned SGLT2 inhibitors, including dapagliflozin, as essential components of modern diabetes management.

Ebymect is indicated for the treatment of type 2 diabetes mellitus in adults as an adjunct to diet and exercise to improve glycemic control in the following situations: (1) when metformin alone does not provide adequate glycemic control; (2) when the patient is already being treated with the combination of dapagliflozin and metformin as separate tablets and wishes to simplify their regimen; and (3) in combination with other antidiabetic medicinal products, including insulin, when these together with metformin do not provide adequate glycemic control. Ebymect is not indicated for the treatment of type 1 diabetes or for the management of diabetic ketoacidosis.

What Should You Know Before Taking Ebymect?

Contraindications

There are several situations in which Ebymect must not be used. You should not take Ebymect if you have a known hypersensitivity (allergy) to dapagliflozin, metformin, or any of the excipients in the formulation. Additionally, Ebymect is contraindicated in the following conditions:

• Type 1 diabetes: Ebymect is designed exclusively for type 2 diabetes. Patients with type 1 diabetes require insulin therapy and should not use SGLT2 inhibitors for glycemic control due to the risk of diabetic ketoacidosis.
• Diabetic ketoacidosis (DKA): A dangerous complication involving high blood sugar and buildup of acids (ketones) in the blood. SGLT2 inhibitors have been associated with cases of atypical DKA, sometimes presenting with near-normal blood glucose levels (euglycemic DKA).
• Severe renal impairment: Ebymect should not be used in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m². This restriction is primarily driven by the metformin component, which relies on renal clearance and can accumulate to dangerous levels when kidney function is significantly impaired, increasing the risk of lactic acidosis.
• Conditions causing lactic acidosis: Including severe infection, septic shock, acute heart failure with hemodynamic instability, respiratory failure, recent myocardial infarction, severe hepatic insufficiency, and alcoholism. These conditions impair tissue oxygenation and lactate clearance, creating the conditions for metformin-associated lactic acidosis.
• Severe hepatic impairment: Liver disease impairs lactate clearance and increases the risk of lactic acidosis with metformin.
• Acute alcohol intoxication: Excessive alcohol consumption potentiates the effect of metformin on lactate metabolism.

Warnings and Precautions

Before starting Ebymect and at regular intervals during treatment, your doctor should assess the following:

• Kidney function: eGFR should be measured before initiating Ebymect and at least annually thereafter. In patients with eGFR approaching 60 mL/min/1.73 m², monitoring should be performed every 3–6 months. Ebymect should not be initiated if eGFR is below 60 mL/min/1.73 m² and must be discontinued if eGFR persistently falls below 30 mL/min/1.73 m².
• Volume depletion: Dapagliflozin causes osmotic diuresis, which may lead to dehydration. Patients at higher risk include the elderly, those taking diuretics (especially loop diuretics), and those with low blood pressure. Ensure adequate fluid intake, particularly during hot weather, illness, or vigorous exercise.
• Diabetic ketoacidosis (DKA): Rare cases of DKA have been reported in patients using SGLT2 inhibitors, including atypical presentations with only moderately elevated blood glucose (euglycemic DKA). Risk factors include a low carbohydrate diet, dehydration, acute illness, surgery, alcohol abuse, and reduced insulin doses. If DKA is suspected, Ebymect should be discontinued immediately.
• Genital infections: By increasing urinary glucose excretion, dapagliflozin creates an environment favorable for fungal overgrowth, leading to an increased incidence of genital mycotic infections (vulvovaginal candidiasis in women; balanitis in men). Patients should be counseled on hygiene and advised to seek treatment promptly if symptoms occur.
• Urinary tract infections: SGLT2 inhibitors are associated with a slightly increased risk of urinary tract infections. Complicated urinary tract infections, including pyelonephritis and urosepsis, have been reported rarely.
• Necrotizing fasciitis of the perineum (Fournier’s gangrene): Very rare but serious cases of necrotizing fasciitis of the genital and perineal area have been reported with SGLT2 inhibitors. Seek medical attention immediately if you develop pain, tenderness, redness, or swelling in the genital or perineal area accompanied by fever or general malaise.

Pregnancy and Breastfeeding

Ebymect should not be used during pregnancy. There are limited data on the use of dapagliflozin in pregnant women. Animal studies with dapagliflozin have shown adverse effects on kidney development in the fetus when exposed during the period corresponding to the second and third trimesters of human pregnancy. Metformin crosses the placenta, and while it has been used in gestational diabetes, the combination product Ebymect has not been studied in pregnancy. If pregnancy is detected or planned, Ebymect should be discontinued and treatment switched to insulin, which is the recommended therapy for blood glucose control during pregnancy.

Dapagliflozin and metformin are both excreted in the milk of lactating rats. It is not known whether dapagliflozin is excreted in human breast milk, although metformin is present in human breast milk in small quantities. A risk to the nursing infant cannot be excluded. Ebymect should not be used during breastfeeding. Discuss alternative treatment options with your healthcare provider if you wish to breastfeed.

Elderly Patients

Elderly patients (aged 75 years and over) may be more susceptible to the volume-depleting effects of dapagliflozin (dehydration, dizziness, falls) and may have reduced kidney function. Kidney function should be monitored more frequently in elderly patients. Caution is advised, particularly in patients receiving diuretics or antihypertensive medications, as the additional fluid loss from dapagliflozin may increase the risk of symptomatic hypotension. Metformin is substantially excreted by the kidneys, and because elderly patients are more likely to have decreased renal function, careful dose selection and regular monitoring are recommended.

Driving and Operating Machinery

Ebymect has no or negligible influence on the ability to drive and use machines. However, patients should be aware that dizziness or lightheadedness may occur, particularly at the beginning of treatment, due to the mild diuretic effect of dapagliflozin. If affected, patients should not drive or operate machinery until symptoms resolve. When Ebymect is used in combination with sulfonylureas or insulin, the risk of hypoglycemia is increased, which could impair the ability to drive safely.

How Does Ebymect Interact with Other Drugs?

Understanding drug interactions is essential for the safe use of Ebymect, as both active components – dapagliflozin and metformin – have distinct interaction profiles. While dapagliflozin has relatively few pharmacokinetic interactions, metformin has well-characterized interactions that require careful management. The following sections describe the most clinically relevant interactions organized by their significance.

Major Interactions

Minor Interactions and Monitoring

Dapagliflozin is primarily metabolized by UDP-glucuronosyltransferase 1A9 (UGT1A9) and is not a substrate for or a significant inhibitor of cytochrome P450 (CYP) enzymes. Therefore, dapagliflozin has a low potential for pharmacokinetic drug interactions. Clinical studies have confirmed no significant interaction between dapagliflozin and pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.

Metformin is not metabolized by hepatic enzymes and is excreted unchanged in the urine. Drugs that affect renal function or renal tubular secretion (such as cimetidine, ranolazine, trimethoprim, and vandetanib) can alter metformin clearance. Cationic drugs that are eliminated by renal tubular secretion have the potential to interact with metformin by competing for common renal tubular transport systems. Patients taking such drugs together with Ebymect should be monitored closely and may require dose adjustments.

What Is the Correct Dosage of Ebymect?

Ebymect should always be used exactly as prescribed by your doctor. The dosage is individualized based on your current diabetes treatment regimen, kidney function, and glycemic control targets. The fixed-dose combination allows simplification of treatment by reducing the number of separate tablets taken daily, which can improve medication adherence – a critical factor in long-term diabetes management.

Adults

Ebymect should be taken orally, twice daily with meals (preferably with breakfast and the evening meal). Taking the medication with food significantly reduces the incidence of gastrointestinal side effects associated with metformin, including nausea, vomiting, diarrhea, and abdominal discomfort. Tablets should be swallowed whole with a glass of water and should not be crushed, chewed, or split.

The maximum recommended daily dose of dapagliflozin is 10 mg (achieved with two tablets of Ebymect 5 mg/850 mg). The maximum recommended daily dose of metformin depends on the formulation: with Ebymect 5 mg/850 mg, the maximum metformin dose is 1,700 mg per day (850 mg twice daily). Your doctor may adjust the total daily metformin dose based on your glycemic control and tolerability.

Children and Adolescents

The safety and efficacy of Ebymect have not been established in children and adolescents under 18 years of age. Ebymect should not be used in this population. Type 2 diabetes in children and adolescents is typically managed with metformin monotherapy and/or insulin under specialist supervision.

Elderly Patients

No dose adjustment is specifically required for elderly patients based on age alone. However, kidney function declines with age, and since metformin is excreted renally, regular monitoring of eGFR is essential. In patients aged 75 years and above, the risks associated with volume depletion from dapagliflozin should be considered, including dizziness, falls, and hypotension. Individual dose titration should be guided by kidney function, overall health status, and tolerability.

Renal Impairment

Kidney function is the primary determinant of Ebymect dosing eligibility. The following guidelines apply:

• eGFR ≥ 60 mL/min/1.73 m²: No dose adjustment needed. Standard dosing applies.
• eGFR 45–59 mL/min/1.73 m²: Do not initiate Ebymect. If already taking Ebymect and eGFR falls into this range, assess benefit/risk. The maximum daily dose of metformin is 1,000 mg.
• eGFR 30–44 mL/min/1.73 m²: Do not initiate Ebymect. If already taking Ebymect and eGFR declines to this range, reduce metformin dose (maximum 500 mg twice daily) and monitor closely.
• eGFR < 30 mL/min/1.73 m²: Ebymect is contraindicated. Discontinue immediately.

Missed Dose

If you forget to take a dose of Ebymect, take it as soon as you remember, provided it is not close to the time for your next scheduled dose. Do not take a double dose to make up for a forgotten one. If it is almost time for your next dose, skip the missed dose and return to your regular schedule. Consider setting a daily reminder or using a pill organizer to help maintain consistent dosing.

Overdose

If you suspect you have taken more Ebymect than prescribed, seek medical attention immediately. Overdose of the metformin component is the primary concern, as it can lead to lactic acidosis, a life-threatening condition. Symptoms of metformin overdose include nausea, vomiting, diarrhea, abdominal pain, rapid breathing (Kussmaul breathing), drowsiness, and hypothermia. Lactic acidosis requires emergency hospital treatment, and metformin can be removed from the blood by hemodialysis. No specific antidote exists for dapagliflozin overdose, but supportive measures including monitoring of blood glucose, hydration status, and electrolytes should be implemented.

What Are the Side Effects of Ebymect?

Like all medicines, Ebymect can cause side effects, although not everybody gets them. The side effect profile of Ebymect reflects the combined known effects of its two active components – dapagliflozin and metformin. Understanding the frequency and nature of potential side effects helps patients and healthcare providers make informed decisions about treatment and recognize symptoms that may require medical attention.

Side effects are classified according to their frequency based on clinical trial data and post-marketing surveillance. The frequency categories are defined as follows: very common (affects more than 1 in 10 people), common (affects 1 in 10 to 1 in 100 people), uncommon (affects 1 in 100 to 1 in 1,000 people), rare (affects 1 in 1,000 to 1 in 10,000 people), and very rare (affects fewer than 1 in 10,000 people).

The gastrointestinal side effects of metformin (nausea, vomiting, diarrhea, abdominal pain) are the most frequently reported adverse events and are a leading cause of treatment discontinuation. These effects are dose-dependent and most often occur during the first weeks of treatment. They can be significantly reduced by taking Ebymect with meals and by gradual dose titration at the start of treatment. Most patients find that gastrointestinal symptoms diminish substantially after the first 2–4 weeks of continued use.

Genital infections (candidiasis in women, balanitis in men) are a well-known class effect of SGLT2 inhibitors and are directly related to the increased glucose concentration in the urine, which promotes fungal overgrowth. These infections are generally mild to moderate in severity and respond well to standard antifungal treatment. Maintaining good genital hygiene and keeping the area dry can help reduce the risk. Patients who have a history of recurrent genital fungal infections may be at higher risk.

Long-term use of metformin (over several years) has been associated with decreased absorption of vitamin B12 in approximately 5–10% of patients. This can occasionally lead to clinically significant vitamin B12 deficiency, manifesting as megaloblastic anemia or peripheral neuropathy. Periodic monitoring of vitamin B12 levels is recommended, particularly in patients with symptoms suggestive of deficiency (fatigue, numbness, tingling in extremities) or in patients with risk factors for B12 deficiency (elderly, vegetarian diet, malabsorption disorders).

How Should You Store Ebymect?

Proper storage of Ebymect is important to ensure the medication remains effective and safe throughout its shelf life. The following guidelines should be followed:

• Temperature: Store below 30°C (86°F). Do not refrigerate or freeze.
• Moisture protection: Store in the original blister packaging to protect from moisture. The film-coated tablets are sensitive to humidity, and exposure to moisture can compromise their integrity.
• Light: No special precautions needed regarding light exposure.
• Expiry date: Do not use Ebymect after the expiry date stated on the blister and outer carton. The expiry date refers to the last day of that month.
• Damaged tablets: Do not use tablets that appear discolored, damaged, or show visible signs of deterioration.
• Children: Keep Ebymect out of the sight and reach of children.
• Disposal: Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment.

If you are traveling with Ebymect, keep the tablets in their original packaging and ensure they are not exposed to extreme temperatures (such as inside a hot car or in freezing conditions during air travel in the luggage hold). When traveling across time zones, maintain your regular dosing schedule as closely as possible and consult your doctor or pharmacist for specific advice about managing your medication during travel.

What Does Ebymect Contain?

Active Substances

Each film-coated tablet of Ebymect contains:

• Dapagliflozin: 5 mg (as dapagliflozin propanediol monohydrate, equivalent to 6.15 mg of the monohydrate salt). Dapagliflozin is a potent, selective, and reversible inhibitor of SGLT2 with an oral bioavailability of approximately 78%. It is extensively bound to plasma proteins (approximately 91%).
• Metformin hydrochloride: 850 mg (equivalent to approximately 663 mg metformin base). Metformin has an oral bioavailability of 50–60% and is distributed rapidly into body tissues, with negligible binding to plasma proteins.

Inactive Ingredients (Excipients)

The excipients in Ebymect serve various pharmaceutical functions to ensure tablet stability, appropriate dissolution, and ease of swallowing. The inactive ingredients include:

• Tablet core: Hydroxypropylcellulose (binder), microcrystalline cellulose (diluent/filler), magnesium stearate (lubricant), sodium starch glycolate (disintegrant).
• Film coating: Polyvinyl alcohol (film-forming agent), titanium dioxide (E171, opacifier and colorant), macrogol 3350 (plasticizer), talc (anti-tacking agent), iron oxide yellow (E172, colorant), iron oxide red (E172, colorant).

Patients with known allergies or intolerances to any of these excipients should inform their healthcare provider before starting Ebymect. The tablet does not contain lactose, gluten, or gelatin.

Physical Description

Ebymect 5 mg/850 mg tablets are brown, oval, biconvex, film-coated tablets approximately 20 mm in length, debossed with “5/850” on one side and “1067” on the other side. The tablets are packaged in PVC/Aluminium blisters in pack sizes of 28, 56, or 60 tablets, though not all pack sizes may be marketed in every country.